Milestone Pharmaceuticals Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
MIST$0.74-3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets** (Unaudited)**
(in thousands of US dollars, except share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| · September 30, 2025 · December 31, 2024 | ||||||
| Assets | | | | |||
| | | | | | | |
| Current assets · · · · | ||||||
| Cash and cash equivalents | | $46,685 | $25,314 | |||
| Short-term investments | | | 35,900 | | | 44,381 |
| Research and development tax credits receivable | | | 808 | | 901 | |
| Prepaid expenses | | | 2,577 | | 1,840 | |
| Other receivables | | | 700 | | 1,490 | |
| Total current assets | | | 86,670 | | 73,926 | |
| Operating lease right-of-use assets | | | 944 | | | 1,376 |
| Property and equipment | | | 136 | | 197 | |
| Total assets | | $87,750 | $75,499 | |||
| | | | | | | |
| Liabilities, and Shareholders' Equity | | | | |||
| | | | | | | |
| Current liabilities | | | | |||
| Accounts payable and accrued liabilities | | $10,041 | $7,555 | |||
| Operating lease liabilities | | | 483 | | 571 | |
| Total current liabilities | | | 10,524 | | 8,126 | |
| Operating lease liabilities, net of current portion | | | 519 | | 874 | |
| Senior secured convertible notes | | | 56,206 | | | 53,352 |
| Total liabilities | | | 67,249 | | 62,352 | |
| | | | | | | |
| | | | | | | |
| Shareholders’ Equity | | | | | ||
| Common shares, no par value, unlimited shares authorized, 85,169,344 shares issued and outstanding as of September 30, 2025, 53,353,984 shares issued and outstanding as of December 31, 2024 | | | 311,776 | | 288,048 | |
| Pre-funded warrants - 16,412,925 issued and outstanding as of September 30, 2025 and 12,910,590 as of December 31, 2024 | | | 55,649 | | | 53,076 |
| Additional paid-in capital | | | 66,270 | | 39,568 | |
| Accumulated deficit | | | (413,194) | | (367,545) | |
| | | | | | | |
| Total shareholders’ equity | | | 20,501 | | 13,147 | |
| | | | | | | |
| Total liabilities and shareholders’ equity | | $87,750 | $75,499 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.